How Do Foreign Biotech Companies Handle China’s Human Genetic Resource (HGR) Export Rules?

China’s human genetic resource (HGR) regulations represent one of the most complex and consequential compliance challenges facing foreign biotech companies conducting clinical trials or genomic research in China. The regulatory framework, centered on the Regulations on the Management of Human Genetic Resources (effective July 1, 2024, superseding the 1998 interim measures) and its implementing rules, imposes strict controls on the collection, use, and — most critically — the export or transfer of Chinese human genetic resources and associated data.

This comprehensive FAQ provides foreign biotech companies with a practical guide to navigating China’s HGR export rules, covering the approval pathways, prohibited activities, compliance strategies, common pitfalls, and recent enforcement trends as of 2025–2026.

The Regulatory Framework: Understanding What Is Regulated

China’s HGR regulations define “human genetic resources” broadly to include: (1) human genetic materials such as organs, tissues, cells, DNA, RNA, and genome samples; and (2) related data, including genomic sequencing data, clinical data from which genetic information can be derived, and biological sample-derived analytical results. Foreign biotech companies must understand that both physical samples and digital genetic data are subject to export controls — a scope that encompasses most clinical trial biomarker data, genomic sequencing results, and even aggregated genetic statistics.

Key Entities and Their Roles

The Two Approval Pathways: Export vs. International Cooperation

Foreign biotech companies have two main regulatory pathways for handling HGR that involves data or sample transfer outside China:

Pathway 1: HGR Export/Transfer Approval (对外提供/开放使用)

This pathway applies when a foreign biotech company needs to physically transfer human genetic samples or access genetic data from outside China. The application must be submitted by the Chinese research institution partner through the Ministry of Science and Technology (MOST) online platform. Key requirements include:

• Ethics committee approval from the Chinese institution where samples were collected
• Informed consent forms that specifically address intended use, data sharing with foreign entities, and the scope of genetic analysis
• Detailed export plan specifying the type and quantity of HGR, purpose of export, destination country, and recipient entity
• Data security assessment demonstrating compliance with China’s Data Security Law and Personal Information Protection Law
• Approval timeline: 20–30 working days for standard applications; 40–60 working days for complex multi-site exports

Pathway 2: International Cooperative Research Approval (国际合作研究)

This pathway applies when foreign and Chinese entities collaborate on research involving HGR within China, even if no physical export occurs. While the data remains in China, the foreign entity’s “access” to the data — including remote database queries — is considered a form of HGR utilization requiring approval. This pathway is the most common mechanism for foreign biotech companies conducting clinical trials in China:

• Application scope: All international clinical trials involving Chinese subjects where the foreign sponsor will access or analyze HGR-derived data
• Required documentation: Cooperative research agreement, ethics approvals, informed consent forms, data management plan, data security assessment, and IP ownership arrangements
• Approval timeline: 30–45 working days (standard); can be expedited to 20 working days for urgent public health-related research
• Validity period: Typically aligned with the clinical trial duration, up to 5 years

Step-by-Step Compliance Process

Foreign biotech companies should follow this structured approach to HGR compliance:

Step 1: Determine Applicability

Not all clinical data triggers HGR regulations. Data that does not contain genetic information — such as standard vital signs, standard blood chemistry panels, and non-genetic medical imaging — generally falls outside HGR scope. However, any genomic sequencing data, pharmacogenomic data, or biomarker analysis involving DNA/RNA is clearly within scope. When in doubt, err on the side of filing an application — the penalties for non-compliance far outweigh the administrative burden of an unnecessary application.

Step 2: Identify and Engage a Qualified Chinese Partner

The foreign biotech company cannot be the applicant — a Chinese research institution must serve as the primary applicant and custodian. For clinical trials, this is typically the leading study hospital. The Chinese partner must:

• Have legal status as a Chinese legal person (not a foreign-invested entity)
• Have appropriate facilities for HGR storage and processing
• Appoint a dedicated HGR compliance officer
• Establish an internal HGR management system

Step 3: Prepare the HGR Application Package

The application package typically includes:

• Application form (online through the MOST platform)
• Ethics committee approval letter from the Chinese institution
• Informed consent form template (Chinese language version)
• International cooperative research agreement (Chinese and English versions)
• Data management and security plan
• IP ownership and benefit-sharing agreement
• Biosecurity assessment (for export of physical samples)
• Proval letter from the foreign entity’s competent authority (if required by the destination country)

Step 4: Submit and Track the Application

Applications are submitted through the MOST online platform (https://gr.most.gov.cn). The Chinese partner institution submits; the foreign entity may not submit directly. The review process includes:

• Preliminary review: 5 working days — the provincial science and technology department checks completeness
• Technical review: 15–20 working days — MOST evaluates scientific merit, ethical compliance, and national security implications
• Supplementary materials: If requested, the Chinese partner has 30 days to respond; the review clock resets
• Decision: Approval, conditional approval (with modifications), or rejection

Step 5: Establish Ongoing Compliance Monitoring

After approval, foreign biotech companies must implement ongoing compliance measures:

• Annual reporting on HGR usage to MOST
• Real-time tracking of all HGR samples and data within the Chinese partner’s system
• GCP-compliant documentation of all sample collection and processing steps
• Periodic internal audits of HGR compliance
• Prompt reporting of any HGR-related adverse events or data breaches

Prohibited Activities and Penalties

The 2024 Regulations significantly increased penalties for HGR violations, making compliance non-negotiable for foreign biotech companies:

Penalties for violations include:

• Administrative fines: Up to RMB 10 million (approximately USD 1.4 million) for serious violations
• Suspension or revocation of HGR qualifications: Loss of ability to conduct any HGR-related research in China
• Blacklisting of the Chinese partner institution: Affecting all future research collaborations involving that institution
• Criminal liability: For egregious violations involving national security implications, individuals may face criminal prosecution with potential imprisonment of 3–10 years
• Reputational damage: Public announcements of violations on the MOST website, which can severely impact the foreign company’s standing with Chinese regulators and institutional partners

Practical Compliance Strategies

Leading foreign biotech companies employ the following strategies to manage HGR compliance effectively:

Strategy 1: Localize Data Analysis Infrastructure

Rather than exporting raw genomic data, establish a local bioinformatics analysis pipeline within China. Under this model, sequencing data generated in China is processed on servers located in China, and only aggregate results (which may not qualify as HGR) are shared with global headquarters. This approach, while requiring capital investment in local computing infrastructure, significantly reduces the regulatory burden and approval timeline. Several foreign biotech companies have established joint bioinformatics centers in Shanghai and Beijing specifically for this purpose.

Strategy 2: Use the “Green Channel” for Emergency Approvals

For clinical trials addressing urgent public health needs (pandemic response, rare disease treatments with no approved alternatives), MOST maintains an expedited review pathway that can reduce approval timelines by 50–60%. Foreign biotech companies should request this designation when eligible and clearly document the public health rationale.

Strategy 3: Implement a Centralized HGR Compliance Database

Maintain a single source of truth for all HGR-related documentation — applications, approvals, amendments, annual reports, and audit results. Given the volume of documentation required for multi-site clinical trials, a centralized compliance database (accessible to both the Chinese partner and the foreign entity) prevents documentation gaps that could trigger regulatory findings during MOST inspections.

Strategy 4: Engage an HGR-Experienced Legal Advisor

The HGR regulatory landscape is evolving rapidly, with new implementing rules and guidance documents published frequently. Foreign biotech companies should retain Chinese legal counsel with specific HGR experience, not general life science regulatory experience. The nuances of application drafting — particularly the data management plan and benefit-sharing arrangement — significantly influence approval outcomes.

Recent Enforcement Trends (2024–2026)

MOST has significantly increased HGR enforcement activity since the 2024 Regulations took effect:

• Inspection frequency: The number of on-site HGR compliance inspections increased by 150% between 2023 and 2025
• Rejection rates: HGR export applications face an approximately 15–20% rejection rate for initial submissions, most commonly due to inadequate informed consent documentation or insufficient benefit-sharing arrangements
• Application processing times: Average time from submission to approval increased from 25 working days (2022) to 35 working days (2025) as MOST has deepened its technical review
• Cross-agency coordination: MOST now routinely coordinates with the Cyberspace Administration of China (CAC) for data security reviews, adding 10–15 working days to complex applications involving large genomic datasets
• Industry focus: Cell and gene therapy companies, direct-to-consumer genetic testing firms, and large-scale biobank projects face the highest scrutiny

Conclusion

Navigating China’s human genetic resource export rules is one of the most demanding regulatory challenges facing foreign biotech companies in 2026. The framework requires a multi-layered compliance approach: identifying the correct approval pathway, engaging a qualified Chinese partner, preparing comprehensive application documentation, establishing local data analysis infrastructure where feasible, and maintaining ongoing compliance monitoring throughout the research lifecycle.

While the regulatory burden is significant, it is manageable with proper planning and expert guidance. Foreign biotech companies that invest in HGR compliance infrastructure from the outset — rather than treating it as an afterthought — benefit from faster regulatory timelines, stronger Chinese partner relationships, and reduced legal risk. The Chinese market remains too important for global biotech innovation to bypass, and a well-executed HGR compliance strategy is the key to unlocking its potential.